Skip to main
VNRX
VNRX logo

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 88%
Buy 13%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX Ltd is leveraging its Nucleosomics platform to develop cost-effective diagnostic blood tests, with a focus on various diseases, including cancers and conditions linked to NETosis. The company's successful validation of the Nu.Q Lung Cancer Test is anticipated to attract strategic partnerships with major diagnostic and pharmaceutical players, which could significantly de-risk its technology and enhance its market presence. Furthermore, with the introduction of the Nu.Q Vet Cancer Test in over 1,000 Japanese veterinary hospitals, supported by a partnership with Fujifilm Vet Systems, VolitionRX is well-positioned to expand its market reach and drive revenue growth through increased adoption of its innovative diagnostic tools in both human and animal health sectors.

Bears say

VolitionRX Ltd is working on a study aimed at reducing the high false-positive rates in low-dose computed tomography (LDCT) screenings for pulmonary nodules, a challenge that may hinder its diagnostic capabilities and market acceptance. Despite its innovative Nucleosomics platform aimed at developing cost-effective blood tests for various diseases, the company's focus on addressing complex diagnostic issues could delay revenue generation and market penetration. Additionally, the potential for unnecessary invasive procedures stemming from current screening methods raises concerns about the company's ability to create a competitive advantage in a challenging healthcare landscape.

Volitionrx Limited (VNRX) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 88% of analysts recommend a Strong Buy, 13% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Sep 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.